Optimal Radiotherapy Dose in Anal Cancer: Trends in Prescription Dose and Association with Survival
- 1 March 2021
- journal article
- research article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (1) , 229-236
Abstract
Purpose Definitive chemoradiotherapy represents a standard of care treatment for localized anal cancer. National Comprehensive Cancer Network guidelines recommend radiotherapy (RT) doses of >= 45 Gy and escalation to 50.4-59 Gy for advanced disease. Per RTOG 0529, 50.4 Gy was prescribed for early-stage disease (cT1-2N0), and 54 Gy for locally advanced cancers (cT3-T4 and/or node positive). We assessed patterns of care and overall survival (OS) with respect to the RT dose. Methods The National Cancer Database identified patients with non-metastatic anal squamous cell carcinoma from 2004 to 2015 treated with chemoradiotherapy. Patients were stratified by RT dose: 40-< 45, 45-< 50, 50-54, and > 54-60 Gy. Crude and adjusted hazard ratios (HR) were computed using Cox regression modeling. Results A total of 10,524 patients were identified with a median follow-up of 40.7 months. The most commonly prescribed RT dose was 54 Gy. On multivariate analysis, RT doses of 40-< 45 Gy were associated with worse OS vs. 50-54 Gy (HR 1.68 [1.40-2.03],P < 0.0001). There was no significant difference in OS for patients who received 45-< 50 or > 54-60 Gy compared with 50-54 Gy. For early-stage disease, there was no significant association between RT dose and OS. For locally advanced disease, 45-< 54 Gy was associated with worse survival vs. 54 Gy (HR 1.18 [1.04-1.34],P = 0.009), but no significant difference was detected comparing > 54-60 Gy vs. 54 Gy (HR 1.08 [0.97-1.22],P = 0.166). Conclusions For patients with localized anal cancer, RT doses of >= 45 Gy were associated with improved OS. For locally advanced disease, 54 Gy but not > 54 Gy was associated with improved OS.Keywords
This publication has 24 references indexed in Scilit:
- Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)British Journal of Cancer, 2010
- Evaluation of Planned Treatment Breaks During Radiation Therapy for Anal Cancer: Update of RTOG 92-08International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal CanalJAMA, 2008
- Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.Journal of Clinical Oncology, 1997
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996
- Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.Journal of Clinical Oncology, 1996
- Combined therapy for cancer of the anal canalDiseases of the Colon & Rectum, 1993
- Definitive Irradiation and Chemotherapy for Radiosensitization in Management of Anal Carcinoma: Interim Report on Radiation Therapy Oncology Group Study No. 8314JNCI: Journal of the National Cancer Institute, 1989
- An evaluation of combined therapy for squamous cell cancer of the anal canalDiseases of the Colon & Rectum, 1984
- Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canalCancer, 1983